

INDEPENDENT AUDITOR'S REPORT

**TO THE MEMBERS OF
CHANDAN PHARMACY LIMITED
(CIN- U52601DL2017PLC322118)
Report on the audit of Financial Statements**

Opinion

We have audited the financial statements of CHANDAN PHARMACY LIMITED ('the Company'), which comprise the Balance Sheet as at March 31, 2023, the Statement of Profit and Loss and Statement of Cash Flows for the year then ended, and a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Accounting Standards prescribed under section 133 of the Act read with Companies (Accounting Standards) Rules, 2021, ("AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2023, its Profit and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Information Other than the Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Board's Report including Annexures to Board's Report and Shareholder's Information but does not include the financial statements and our auditor's report thereon.

- Head Office:** - A-40, I-Thum, Tower-B, 10th Floor, Unit No. 1033, Sector 62, Noida-201005.
Branch Office: - SEJ Plaza - Second Floor, Office No 534, Marve Road, Above N M Medical, Near Nutan School, Off S V Road, Malad (W), Mumbai-400064.
Branch Office: - A-504, Ansal Chamber-1, Bhikaij Cama Place, New Delhi-110066.
CA Saurabh Tyagi: 7718802884, **CA Navodit Tyagi:** 9167436404, **CA Manoj Modi:** 9022059201.
saurabh@msnt.in navodit@msnt.in manoj@msnt.in



Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

Responsibility of Management and those charged with governance for Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the AS and other accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent, and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditors Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but it is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and considered material if, individually or



in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.




Report on other legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, based on our audit we report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c) The Balance Sheet, the Statement of Profit and Loss and the Statement of Cash Flow dealt with by this Report are in agreement with the books of account.
 - d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with the Companies (Accounting Standards) Rules, 2021.
 - e) On the basis of the written representations received from the directors as on 31st March 2023 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2023 from being appointed as a director in terms of Section 164(2) of the Act.
 - f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "Annexure A". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting.
 - g) Provision of section 197 of the Companies Act not applicable to the Private companies, hence this clause is not applicable to the company.
 - h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
 - i) The Company does not have any pending litigation which would impact its financial position.
 - ii) The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii) There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.



- iv) (a) The management has represented that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person or entity, including foreign entity ("Intermediaries"), which the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- (b) The Management has represented, that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the Company from any person or entity, including foreign entity ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
- (c) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.
- (d) The Company has neither declared nor paid any dividend during the year.
2. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the Annexure B, a statement on the matters specified in the paragraph 3 and 4 of the Order, to the extent applicable.

For MSNT & ASSOCIATES LLP
Chartered Accountants
Firm Registration No.018542C/C400322


Navodit Tyagi
Partner
Membership No.-533375
UDIN No: 23533375BGXPWM1280
Place: Noida
Date: 02/09/2023



**Annexure A to the Independent Auditors' Report
Report on the Internal Financial Controls under Clause (i) of sub-section 3 of
Section 143 of the Companies Act, 2013 ('the Act')**

We have audited the internal financial controls over financial reporting of Chandan Hospital Limited ("the Company") as of 31 March 2023 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the 'Guidance Note') and the Standards on Auditing, issued by ICAI and deemed to be prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.



Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that:

- (1) Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
- (2) Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of the Management and directors of the Company; and
- (3) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.


Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2023, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For MSNT & ASSOCIATES LLP
Chartered Accountants
Firm Registration No.018542C/C400322


Navodit Tyagi
Partner
Membership No.-533375
UDIN No: 23533375BGXPWM1280
Place: Noida
Date: 02/09/2023



Annexure B to the Independent Auditor's Report to the Shareholders

The Annexure referred to in our Independent Auditors' Report to the members of the Company on the financial statements for the year ended 31 March 2023, we report that:

- i. In respect of the Company's Property, Plant and Equipment and Intangible Assets:
 - (a) (A) The company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant & Equipment.

(B) The Company has not intangible assets and hence this clause is not applicable.
 - (b) According to the Information and explanations given to us and on the basis of our examination of the record of the Company, the Property, Plant and Equipment's have been physically verified by the management at reasonable intervals; no material discrepancies were noticed on such verification.
 - (c) According to the information and explanations given to us and on the basis of our examination of the record of the Company, the company does not hold any immovable properties and therefore this clause of the order regarding title deed of the immovable property is not applicable.
 - (d) According to the information and explanation given to us and on the basis of our examination of the record of the Company, the Company has not revalued any of its Property, Plant & Equipment (including Right of Use assets) or intangible assets during the year. Accordingly, the reporting under clause 3(i)(d) of the order is not applicable to the company.
 - (e) According to the information and explanation given to us and on the basis of our examination of the record of the Company, no proceedings have been initiated during the year or are pending against the Company as at March 31, 2023 for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made there under.
- ii. (a) As explained to us and on the basis of the records examined by us, in our opinion, physical verification of inventory has been conducted at reasonable intervals by the management. In our opinion, the coverage and procedure of such verification by the management is appropriate. No material discrepancies were noticed on physical verification of inventories by the management as compared to the book records.

(b) The company is not availing any working capital limit in excess of five crore rupees, in the aggregate, from banks or financial institutions on the basis of security of current of current assets.



- iii. In our opinion and based on the information and explanation given to us and based on our examination of record of the Company, Company has not made investments in, provided any guarantee or security or granted any loans or advances, in nature of loans, secured or unsecured to companies, firms, Limited Liability Partnerships, or other parties. Accordingly, Paragraph 3(iii) of the order is not applicable to the Company.
- iv. In our opinion and according to the information and explanations given to us, the company has not either directly or indirectly, granted any loan to any of its directors or to any other person in whom the director is interested, in accordance with the provision of section 185 of the Act and the Company has not made investments through more than two layers of the investment companies in accordance with the provision of section 186 of the Act. Accordingly, Reporting under clause 3(iv) of the Order is not applicable to the Company.
- v. In our opinion and according to the information and explanations given to us, the Company has not accepted any deposits from the Public during the year. Therefore, the directives issued by the Reserve Bank of India and the provisions of sections 73 to 76 or any other relevant provisions of the Act and the Companies (Acceptance of Deposit) Rules, 2015 with regard to the deposits accepted from the public are not applicable.
- vi. The Central Government of India has not prescribed the maintenance of cost records under sub-section (1) of section 148 of the Act for any of the activities of the company and accordingly paragraph 3 (vi) of the order is not applicable
- vii. a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted/ accrued in the books of account in respect of undisputed statutory dues including provident fund, income tax, sales tax, wealth tax, service tax, duty of customs, value added tax, GST, cess and other material statutory dues have been regularly deposited during the year by the Company with the appropriate authorities. As explained to us, the Company did not have any dues on account of employees' state insurance and duty of excise.

According to the information and explanations given to us, no undisputed amounts payable in respect of provident fund, income tax, sales tax, wealth tax, service tax, duty of customs, value added tax, cess, GST and other material statutory dues were in arrears as at 31 March 2023 for a period of more than six months from the date they became payable.

b) According to the information and explanations given to us and the records of the company examined by us, there are no dues of income-tax, sales-tax, service tax,



goods and service tax, duty of customs, duty of excise and value added tax which have not been deposited on account of any dispute.

- viii. There were no transactions relating to previously unrecorded income that have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961).
- ix. (a) Based on our audit procedures and according to the information and explanations given to us, the Company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender.
- (b) According to information and explanation given to us and on the basis of our examination of the records of the Company, the company has not been declared a willful defaulter by any bank or financial institution or any lender.
- (c) Based on our audit procedures and according to the information and explanations given to us, the Company has utilized the term loans for the purpose for which loans were obtained.
- (d) On an overall examination of the financial statements of the Company, funds raised on a short-term basis have, prima facie, not been used during the year for long-term purposes by the Company.
- (e) The company does not hold any investment in any subsidiary, associate, or joint venture (as defined under the act) during the year ended 31st March 2023. Accordingly, 3(ix)(e) and 3(ix)(f) is not applicable.
- x. (a) The Company has not raised money by way of Initial Public offer or further public offer (including debts instruments) during the year. Accordingly, clause 3(x)(a) of the Order is not applicable.
- (b) During the year, the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully or partly or optionally) and hence reporting under clause 3(x)(b) of the order is not applicable.
- xi. (a) To the best of our knowledge and belief and according to the information and explanations given to us, no fraud by the Company or any fraud on the company has been noticed or reported during the year.
- (b) No report under sub-section (12) of section 143 of the Companies Act has been filed in Form-ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and up to date of this report.
- (c) According to the information and explanations given to us by management, no whistle-blower complaints have been received by the Company.
- xii. The Company is not a Nidhi company. Therefore, the provisions of clause 3(xii)(a), 3(xii)(b) and 3(ix)(c) of the Order are not applicable.



- xiii. In our opinion, all transactions with the related parties are in compliance with section 177 and 188 of Companies Act, 2013 where applicable and the details of such transactions have been disclosed in the notes to the financial statements as required by the applicable Accounting Standard.
- xiv. (a) In our opinion and based on our examination, the Company does not comply with the provision of section 138 of the Act. Hence, the provision stated in paragraph 3(xiv)(a) and 3(xiv)(b) of the Order are not applicable to the Company.
- xv. In our opinion and according to the information and explanations given to us, the company has not entered into any non-cash transactions with its directors or persons connected with him and hence provisions of section 192 of the Companies Act, 2013 are not applicable to the Company.
- xvi. (a) In our opinion and based on our examination, the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3 (xvi) (a) of the Order is not applicable to the Company.
- (b) In our opinion and based on our examination, the Company has not conducted any Non-Banking Financial or Housing Finance activities during the year. Accordingly, clause 3 (xvi) (b) of the Order is not applicable to the Company.
- (c) In our opinion and based on our examination, the Company is not a Core Investment Company (CIC) as defined in the regulation made by the Reserve Bank of India. Accordingly, clause 3 (xvi) (c) of the Order is not applicable to the Company.
- (d) According to information and explanations given by the management, the group does not have any CIC as part of the Group.
- xvii. The company has not incurred cash losses during the financial year covered by our audit and the immediately preceding financial year.
- xviii. There has been resignation of the statutory auditors of the company during the year and the outgoing auditor has not raised any issues, objections or concerns.
- xix. According to information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that the Company is not capable of meeting its liabilities existing at the date of balance sheet and when they fail




due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company.

We further state that our reporting is based on facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

- xx. Based on our examination and according to the information and explanations given to us, the provisions of section 135 of the Companies Act are not applicable to the company. Accordingly, clause 3(xx)(a) and 3(xx)(b) of the order are not applicable.
- xxi. As the report is with respect of standalone financial statements, therefore, clause 3(xxi) of the order is not applicable.

For MSNT & ASSOCIATES LLP
Chartered Accountants
Firm Registration No.018542C/C400322


Navodit Tyagi
Partner
Membership No.-533375
UDIN No: 23533375BGXPWM1280
Place: Noida
Date: 02/09/2023



Chandan Pharmacy Limited

Corp. off. Add: Biotech Park, Sector- G, Janakipuram, Kursi Road, Lucknow-226021

CIN: U52601DL2017PLC322118

Balance Sheet as at 31-Mar-2023

In ₹ (Lakhs)

Particulars	Note No.	as at 31-Mar-2023	as at 31-Mar-2022
I. EQUITY AND LIABILITIES			
1 Shareholders' Funds		546.66	499.32
(a) Share Capital	4	32.30	32.30
(b) Reserves and Surplus	5	514.36	467.02
(c) Money Received Against Share Warrants		-	-
2 Share Application money pending allotment		-	-
3 Non-Current Liabilities		0.12	-
(a) Long-Term Borrowings		-	-
(b) Deferred Tax Liabilities (Net)		0.12	-
(c) Other Long-Term Liabilities		-	-
(d) Long-Term Provisions		-	-
4 Current Liabilities		2,291.78	1,156.27
(a) Short-Term Borrowings	6	478.12	-
(b) Trade Payables	7	-	-
(i) Total outstanding dues of micro and small enterprises		216.70	83.78
(ii) Total outstanding dues of other than micro and small enterprises		240.86	651.79
(c) Other Current Liabilities	8	1,307.07	168.64
(d) Short-Term Provisions	9	46.02	52.05
Total		2,838.56	1,655.58
II. ASSETS			
1 Non-Current Assets		806.73	750.12
(a) (i) Property, Plant and Equipment	10	37.73	10.80
(ii) Capital Work-in-Progress		-	-
(iii) Intangible Assets		-	-
(iv) Intangible Assets under Development		-	-
(b) Non-Current Investments	11	114.75	114.75
(c) Deferred Tax Assets (Net)		-	0.00
(d) Long-Term Loans and Advances	12	720.39	120.49
(e) Other Non-Current Assets	13	7.37	4.00
2 Current Assets		1,957.83	1,405.46
(a) Current Investments		-	-
(b) Inventories	14	951.31	533.00
(c) Trade receivables	15	0.36	827.67
(d) Cash and Cash Equivalents	16	35.82	28.81
(e) Short-Term Loans and Advances	17	970.54	215.08
(f) Other Current Assets		-	-
Total		2,838.56	1,655.58

SIGNIFICANT ACCOUNTING POLICIES AND NOTES ON ACCOUNTS

1, 2 & 3

The Notes referred to above form an integral part of the Balance Sheet.

As per our report of even date
For M/S MSNT & Associates
Chartered Accountants
Firm Reg. No. 018542C

(CA, Navodit Tyagi)
Partner

Membership No. - 533375

Address - A-40, I THUM, Town-B, 10th Floor, Sec-62, Noida

Place: Noida

Date: 02/09/2023

UDIN - 23533375/BCKPMM1260



For and On behalf of the Board

(Signature)

(Dr. Amar Singh)
Director

(Signature)

(Asmita Singh)
Director



Chandan Pharmacy Limited

Corp. off. Add.: Biotech Park, Sector- G, Jankipuram, Kursi Road, Lucknow-226021
CIN: U52601DL2017PLC322118

Statement of Profit and Loss for the year ended 31-Mar-2023

In ₹ (Lakh)

Particulars	Note No.	1-Apr2022 to 31-Mar2023	1-Apr2021 to 31-Mar2022
I Revenue from Operations	18	5,907.69	4,446.79
II Other Income	19	2.17	2.27
III TOTAL REVENUE (I + II)		5,909.86	4,449.06
IV EXPENSES			
Cost of Materials Consumed			
Purchases of Stock-in-Trade	20	5,330.15	4,183.00
Changes in Inventories	21	(418.32)	(190.54)
Employee Benefit Expenses	22	324.77	199.92
Finance Costs	23	32.92	1.08
Depreciation and Amortization Expenses	24	3.49	1.16
Other Expenses	25	572.93	250.29
TOTAL EXPENSES		5,845.94	4,444.92
V Profit before Exceptional and Extraordinary Items and Tax (III-IV)		63.92	4.14
VI Exceptional Items			
VII Profit before Extraordinary Items and Tax		63.92	4.14
VIII Extraordinary Items			
IX Profit Before Tax		63.92	4.14
X Tax Expense			
Current Tax		16.46	1.44
Deferred Tax		0.12	
XI Profit/(Loss) for the period from Continuing Operations (IX-X)		47.34	2.70
XII Profit/(Loss) from Discontinuing Operations			
XIII Tax Expense of Discontinuing Operations			
XIV Profit/(Loss) from Discontinuing Operations (after tax) (XII-XIII)			
XV Profit/(Loss) for the Period (XI+XIV)		47.34	2.70
XVI Earnings per Equity Share			
-Basic			
-Diluted			

SIGNIFICANT ACCOUNTING POLICIES AND NOTES ON ACCOUNTS

1, 2 & 3

The Notes referred to above form an integral part of the Balance Sheet.

As per our report of even date

For M/S MSNT & Associates

Chartered Accountants

Firm Reg. No. 018542C

(CA. Narendr Tyagi)

Partner

Membership No. - 533375

Address - A-40, I-THUM, Tower-B, 10th Floor, Sec-62, Noida.


Place: Noida


Date: 02/09/2023

UDIN: 23533375BGXPWM1280



For and On behalf of the Board


(Dr. Amar Singh)
Director


(Aamita Singh)
Director



CHANDAN PHARMACY LIMITED

Corp. off. Add.: Biotech Park, Sector- G, Jankipuram, Kursi Road, Lucknow-226021

CIN: U52601DL2017PLC322118

www.chandan.co.in

Significant Accounting Policies and Notes forming part of the Financial Statements

1. COMPANY OVERVIEW

The Company is engaged in the business of trading of medicine and providing medical diagnostic services to individuals and corporate.

2. SIGNIFICANT ACCOUNTING POLICIES

a) Basis of Preparation of Financial Statements

The Financial Statements are prepared under historical cost convention and on the accrual & going concern basis, in accordance with the generally accepted accounting principles (GAAP) in India, GAAP comprises mandatory accounting standards as prescribed under Section 133 of the Companies Act, 2013 ('Act') read with Rule 7 of the Companies (Accounts) Rules, 2014, the provisions of the Act (to the extent notified).

Accounting policies have been consistently applied except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy hitherto in use.

All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set out in Revised Schedule VI to the Companies Act, 1956. Based on the nature of the services and their realisation in cash and cash equivalents, the Company has ascertained its operating cycle as twelve months for the purpose of current or non-current classification of assets and liabilities.

The Schedule III of Companies Act 2013 is used for the preparation of financial statements. This has a significant impact on the disclosure and presentation in financial statements. Previous year's figures have been regrouped/ reclassified wherever necessary to correspond with the current year's classification/disclosure. The balances of Personal Account are subject to confirmation & reconciliation. In the opinion of the management, the current assets, loans & advances have a value on realization in the ordinary course of business at least equal to the amount at which they are stated in the Balance Sheet.

b) Use of Estimates

The preparation and presentation of Financial Statements requires estimates and assumptions to be made that affect the reported amount of assets and liabilities and disclosure of contingent liabilities on the date of the Financial Statements and the reported amount of revenues and expenses during the reporting period. Difference between the actual results and estimates is recognised in the period in which the results are known/ materialized.

Accounting estimates could change from period to period. Actual results could differ from those estimates. Appropriate changes in estimates are made as the Management becomes aware of changes in circumstances surrounding the estimates. Changes in estimates are reflected in the financial statements in the period in which changes are made and, if material, their effects are disclosed in the notes to the financial statements.

c) Fixed Assets

(i) Fixed Assets are stated at cost less accumulated depreciation, amortisation and impairment loss, if any.

(ii) Expenses incurred relating to project, prior to commencement of commercial operation, are considered as project development expenditure and shown under Capital Work in Progress.

d) Depreciation/ Amortisation

Depreciation on tangible assets is provided on the Straight line Method as per useful life specified in schedule II of the Companies Act, 2013. Depreciation for assets purchased / sold during a period is proportionately charged. Intangible assets are amortized over their respective individual estimated useful lives on a straight-line basis, commencing from the date the asset is available to the Company for its use. Depreciation and amortization methods, useful lives and residual values are reviewed periodically, including at each financial year end

e) Impairment of Assets

An asset is treated as impaired when the carrying cost of assets exceeds its recoverable value. An impairment loss is charged to the Statement of Profit and Loss in the year in which an asset is identified as impaired. The impairment loss recognised in prior accounting period is increased/ reversed where there has been change in the estimate of recoverable value. The recoverable value is the higher of the assets' net selling price and value in use.

f) Investments

Current Investments are carried at lower of cost and market value computed Investment wise. Long Term Investments are stated at cost or fair value . Provision for diminution in the value of long term investments is made only if such a decline is other than temporary in the opinion of the management. Investments in subsidiaries and associates are held for sale in future.

g) Inventories of Stores/Spares and consumables

Inventories of stores and spares are accounted for at cost or net realizable value, whichever is less. Stocks of consumable items has been charged to profit & Loss account on consumption basis.

h) Revenue Recognition

Revenue is recognized to the extent that it can be reliably measured and is probable that the economic benefit will flow to the company. Revenue from sale of goods is recognized when the significant risks and rewards of ownership of the goods are transferred to the customer.

Sales are accounted net of amount recovered towards excise duty, sales tax and sales returns.

Sales returns are accounted on actual receipt of return goods / settlement of claims.

Services are accounted for pro-rata over the period of contract.

Interest income is recognized on pro-rate basis.

Dividend income is recognized when right to receive the dividend is established.

i) Taxes on Income and Deferred Tax

Provision for Income Tax is made on the basis of taxable income for the year at current rates. Tax expense comprises of Current Tax and Deferred Tax at the applicable enacted or substantively enacted rates. Current Tax represents the amount of Income Tax payable/ recoverable in respect of the taxable income/ loss for the reporting period. Deferred Tax represents the effect of timing difference between taxable income and accounting income for the reporting period that originate in one period and are capable of reversal in one or more subsequent periods.

The Deferred Tax Asset is recognised and carried forward only to the extent that there is a reasonable certainty that the assets will be realised in future. However, where there is unabsorbed depreciation or carried forward loss under taxation laws, Deferred Tax Assets are recognised only if there is virtual certainty of realisation of assets.

Minimum Alternate Tax (MAT) paid in a year is charged to the Statement of Profit and Loss as current tax. The Company recognizes the MAT credit available as an asset only to the extent that there is convincing evidence that the Company will pay the normal income tax during the specified period i.e., period for which MAT credit is allowed to be carried forward.

j) Provisions, Contingent Liabilities and Contingent Assets

Provisions involving substantial degree of estimation in measurement are recognised when there is a present obligation as a result of past events and it is probable that there will be an outflow of resources. A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that

may, but probably will not, require an outflow of resources. When there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made. Contingent assets are neither recognised nor disclosed in the Financial Statements.

k) Earning per Share

In determining Earning per Share, the Company considers the net profit after tax and includes the post tax effect of any extraordinary / exceptional item. The number of shares used in computing Basic Earning per Share is the weighted average number of shares outstanding during the period. The number of shares used in computing Diluted Earning per Share comprises the weighted average shares considered for deriving Basic Earnings per Share and also the weighted average number of shares that could have been issued on the conversion of all dilutive potential equity shares unless the results would be anti - dilutive. Dilutive potential equity shares are deemed converted as of the beginning of the period, unless issued at a later date.

l) Employee Benefits

a. Short term employee benefits

All employee benefits payable wholly within twelve months of rendering the service are classified as short term employee benefits.

b. Long Term Employees benefits

The provision for the Gratuity amount has been estimated and provided for. The present value of obligation under such defined benefit plan is determined based on actuarial valuation. The gratuity obligation recognized in Balance Sheet represent the actual deficit in the Company's defined benefit plans.

m) Lease

Operating Lease

Leases where the lessor effectively retains substantially all the risks and benefits of the leased assets are classified as operating leases. Operating lease payments are recognized in the Statement of Profit and Loss on a straight line basis over the lease term.

Lease agreements are renewable for further period or periods on terms and condition as mutually agreed with the lessor.

Variation or escalations clauses in lease rentals are made as per mutually agreed terms and conditions with the lessor.

n) The Company has a policy to recognize and identify related party transactions; disclosures of related party transactions have been made wherever applicable.

Place: Lucknow
Date: 02/Sep/2023



Dr. Amar Singh
(Director)



Asmita Singh
(Director)

Chandan Pharmacy Limited
Notes to and forming part of Balance Sheet as at 31-Mar-2023

4. Share Capital

In ₹ (Lakh)

Particulars	as at 31-Mar-2023		as at 31-Mar-2022	
	Number	Amount	Number	Amount
Authorised				
49,00,000 Equity Shares of Rs 10/- each	4,900,000	490.00	4,900,000	490.00
(Previous Year 48,00,000 Equity Shares of Rs. 10/- each)				
Issued				
3,22,996 Equity Shares of Rs 10/- each	322,996	32.30	322,996	32.30
(Previous Year 1,50,004 Equity Shares of Rs 10/- each)				
Subscribed and Fully Paid				
3,22,996 Equity Shares of Rs 10/- each	322,996	32.30	322,996	32.30
(Previous Year 1,50,004 Equity Shares of Rs 10/- each)				
TOTAL	322,996	32.30	322,996	32.30

Notes:

a) Shares held by each shareholder holding more than 5% shares as on period end.

Name of shareholder	as at 31-Mar-2023		as at 31-Mar-2022	
	% Held	Shares(Nos)	% Held	Shares(Nos)
Amar Singh	18.58	60,000	40.00	60,000
Anant Singh	12.38	40,000	26.67	40,000
Vinay Lamba	6.19	20,001	13.33	20,001
Asmita Singh	-	-	6.67	10,000
AmarAnita Holdings (India) Private Limited	-	-	6.67	10,001
Chandan Healthcare Limited	53.56	172,992	-	-

b) Reconciliation of opening and closing outstanding no. of shares

Particulars	as at 31-Mar-2023		as at 31-Mar-2022	
	Number	Amount	Number	Amount
Equity Shares Subscribed				
Opening Balance	322,996	32.30	150,004	15.00
Fresh Issue	-	-	172,992	17.30
Bonus	-	-	-	-
Buyback	-	-	-	-
Closing Balance	322,996	32.30	322,996	32.30

5. Reserves and Surplus

Particulars	as at 31-Mar-2023	as at 31-Mar-2022
Surplus		
Opening Balance	467.02	22.62
(+ / -) Net profit/(Net loss) for the Current Year	63.92	2.70
(+ / -) Current Year -Tax	(16.46)	
(+ / -) Dividend	-	(15.00)
(+ / -) Deferred Tax Assets	(0.12)	
(+ / -) Share Premium	0.00	456.70
Closing balance	514.36	467.02
Total	514.36	467.02

6 . Short Term Borrowings

In ₹ (Lakh)

Particulars	as at 31-Mar-2023		as at 31-Mar-2022	
	SECURED	UNSECURED	SECURED	UNSECURED
(a) Secured Loans repayable on demand:				
From Banks	478.12	-	-	-
From Other Parties	-	-	-	-
(b) Loans & Advances from related parties	-	-	-	-
(c) Deposits	-	-	-	-
(d) Other loans and advances	-	-	-	-
(e) Current Maturities of Long Term Borrowings	-	-	-	-
Total	478.12	-	478.12	-

Notes-

Details of Security (Cash Credit Limit):

1. Prime Security :- Hypothecation of all type of stocks and book debits by way of first charge.
2. Collateral Security :- Equitable Mortgage created by way of Deposit of Title Deed on the immovable property.
3. Personal Guarantee of all the Directors

7. Trade Payables

Figures For the Current Reporting Period

In ₹ (Lakh)

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	
MSME	216.70	-	-	-	216.70
Others	240.86	-	-	-	240.86
Dispute dues-MSME	-	-	-	-	-
Dispute dues	-	-	-	-	-
Others	-	-	-	-	-
Total					457.57

Figures For Previous Reporting Period

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	
MSME	83.78	-	-	-	83.78
Others	851.79	-	-	-	851.79
Dispute dues-MSME	-	-	-	-	-
Dispute dues	-	-	-	-	-
Others	-	-	-	-	-
Total					935.57

Chandan Pharmacy Limited
Notes to and forming part of Balance Sheet as at 31-Mar-2023

8. Other Current Liabilities

In ₹ (Lakh)

Particulars	as at 31-Mar-2023	as at 31-Mar-2022
Current Maturities of Finance Lease Obligations	-	-
Interest Accrued but not due on Borrowings	-	-
Interest Accrued and due on Borrowings	-	-
Income Received in Advance	-	-
Unpaid Dividends	-	-
Application money received for allotment of securities and due for refund and interest accrued thereon	-	-
Unpaid matured Deposits and Interest accrued thereon	-	-
Unpaid matured Debentures and Interest accrued thereon	-	-
Other Payables :		
- Creditors for Expenses	419.36	134.54
- Creditors for Rent	0.82	0.18
- Creditors for Fixed Assets	1.53	0.21
- Cheque Issued But Not Cleared	797.75	20.00
- Payable to Professionals	28.28	0.27
- Payable to Staff	53.28	-
- Commission Payable	6.04	-
- Other Payable	-	13.45
Total	1,307.07	168.64

09. Short Term Provision

Particulars	as at 31-Mar-2023	as at 31-Mar-2022
(a) Provision for Employee Benefits	12.94	37.66
(h) Others (specify nature)	-	-
- Audit Fees Payable	-	0.87
- GST Payable	3.21	-
- Income Tax Payable	20.89	9.65
- Statutory Payable	11.99	3.88
Total	49.02	52.06

11. Non-Current Investments

Particulars	as at 31-Mar-2023	as at 31-Mar-2022
(a) Investment property	-	-
(b) Investments in Equity Instruments	114.75	114.75
(c) Investments in preference shares	-	-
(d) Investments in Government or trust securities	-	-
(e) Investments in debentures or bonds	-	-
(f) Investments in Mutual Funds	-	-
(g) Investments in partnership firms	-	-
(h) Other non-current investments (specify nature)	-	-
Total	114.75	114.75

12. Long Term Loans & Advances

In ₹ (Lakh)

Particulars	as at 31-Mar-2023	as at 31-Mar-2022
(a)Capital Advances	-	-
(c)Loans and Advances to Related Parties	715.55	117.71
(h) Other loans and advances (specify nature)	-	-
Secured, considered good;		
- Loan & Advance to Employee	5.34	2.78
Total	720.89	120.49

13. Other Non-Current Assets

Particulars	as at 31-Mar-2023	as at 31-Mar-2022
(a)Security Deposits	7.37	4.00
(b) Other (specify nature)	-	-
Secured, considered good;		
Total	7.37	4.00

14 . Inventories

Particulars	as at 31-Mar-2023	as at 31-Mar-2022
(a) Raw Materials	-	-
(b) Work-in-progress	-	-
(c) Finished goods	-	-
(d) Stock-in-trade	951.31	533.00
(e) Stores and spares	-	-
(f) Loose tools	-	-
(g) Others (specify nature)	-	-
Total	951.31	533.00

16 . Cash and Cash Equivalents

Particulars	as at 31-Mar-2023	as at 31-Mar-2022
(a) Balances with banks		
Earmarked Balances	-	-
In Current Account	28.65	1.26
Margin Money	-	-
Security Against Borrowings	-	-
Guarantees	-	-
Other Commitments (Security/earnest money)	-	-
Bank deposits with more than 12 months maturity	-	-
(b) Cheques, drafts on hand	-	-
(c) Cash on hand	6.97	27.55
(d) Others	-	-
Total	35.62	28.81

17 . Short Term Loans and Advances

In ₹ (Lakh)

Particulars	as at 31-Mar-2023	as at 31-Mar-2022
(a)Loans and Advances to Related Parties	-	-
(b)Other Loans and Advances		
<u>Unsecured, considered good</u>		
- Goods & Service Tax	-	9.06
- Advance for Expenses	4.22	3.06
- Advance to Supplier	29.43	3.46
- Advance for Fixed Assets	0.30	1.38
- Advance Tax	0.11	0.11
- Sundry Debtors	751.23	198.91
- Other Misc Advance	185.25	-
Total	970.54	215.98

Note 15 TRADE RECEIVABLES

Figures For the Current Reporting Period

In ₹ (Lakh)

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 Months	6 Months - 1Year	1-2 Years	2-3 Years	More than 3 Years	
Undisputed Trade Receivables- Considered Goods	0.36	-	-	-	-	0.36
Undisputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Disputed Trade Receivables- Considered Goods	-	-	-	-	-	-
Disputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Others	-	-	-	-	-	-
Total	0.36					0.36

Figures For Previous Reporting Period

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 Months	6 Months - 1Year	1-2 Years	2-3 Years	More than 3 Years	
Undisputed Trade Receivables- Considered Goods	627.67	-	-	-	-	627.67
Undisputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Disputed Trade Receivables- Considered Goods	-	-	-	-	-	-
Disputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Others	-	-	-	-	-	-
Total	627.67					627.67

SCHEDULE - 10

CPL

Schedule Of Fixed Assets & Depreciation as per Companies Act 1956
For the Year ended 31st March 2023

Sno	ASSETS	GROSS BLOCK				DEPRECIATION				WDV AS ON 31/03/2023	WDV AS ON 31/03/2022	
		AS ON 1/4/2022	ADDITIONS DURING THE YEAR	Adj	AS ON 31/03/23	AS ON 1/4/2022	Life	DURING THE YEAR	ADJ			TOTAL
1	Computers	4.35	0.22	-	4.57	3.78	3Yr	0.03		3.80	0.58	
2	Office Equipments	2.34	4.35	-	6.69	1.58	5Yr	0.86		2.45	0.76	
3	Furniture & Fixtures	7.66	8.44	-	16.11	1.36	10Yr	1.05		2.40	6.31	
4	Office Interior and Renovation	3.59	15.98	-	19.56	0.34	5Yr	1.51		1.85	3.25	
5	Electric Installations	-	1.25	-	1.25	-	15Yr	0.04		0.04	-	
6	Plant and Machinery (medical)	-	0.09	-	0.09	-	13Yr	0.01		0.01	-	
	TOTAL	17.95	30.33		48.28	7.06		3.49		10.55	37.73	10.89

In ₹ (Lakh)

Chandan Pharmacy Limited

Notes to and forming part of Statement of Profit and Loss for the year ended 31-Mar-2023

18. Revenue From Operations

In ₹ (Lakh)

Particulars	1-Apr-2022 to 31-Mar-2023	1-Apr-202 to 31-Mar-2022
Sales of Product	5,907.69	4,446.79
Sales of Services	-	-
Other Operating Revenues	-	-
Total	5,907.69	4,446.79

19 . Other Income

Particulars	1-Apr-2022 to 31-Mar-2023	1-Apr-202 to 31-Mar-2022
Interest Income	-	-
Dividend Income	-	-
Net gain/loss on sale of investments	-	-
Other Non-Operating Income	2.17	2.27
Total	2.17	2.27

20 . Purchases of Stock in Trade

Particulars	1-Apr-2022 to 31-Mar-2023	1-Apr-202 to 31-Mar-2022
Purchases of medicine	5,330.15	4,183.00
Total	5,330.15	4,183.00

21 . Change in Inventories

Particulars	1-Apr-2022 to 31-Mar-2023	1-Apr-202 to 31-Mar-2022
Opening Balance	533.00	342.46
Less Closing Balance	951.31	533.00
Total	(418.32)	(190.54)

22. Employee Benefit Expenses

Particulars	1-Apr-2022 to 31-Mar-2023	1-Apr-202 to 31-Mar-2022
Salary & Wages	301.57	182.02
Contribution to PF & Other Funds	8.49	8.55
Staff Welfare Expenses (Bonus etc.)	14.71	9.35
Total	324.77	199.92

23 . Finance Costs

In ₹ (Lakh)

Particulars	1-Apr-2022 to 31-Mar-2023	1-Apr-202 to 31-Mar-2022
Interest	27.67	
Dividend on Redeemable Preference Shares		
Exchange differences regarded as an adjustment to borrowing costs		
Other borrowing costs (specify nature)		
- Processing Charges	4.14	
- Bank Charges	1.12	1.08
Total	32.92	1.08

24. Depreciation and Amortization Expenses

Particulars	1-Apr-2022 to 31-Mar-2023	1-Apr-202 to 31-Mar-2022
Depreciation	3.49	1.16
Total	3.49	1.16

25. Other Expenses

Particulars	1-Apr-2022 to 31-Mar-2023	1-Apr-202 to 31-Mar-2022
Payment to Auditors		
As Auditor	0.40	0.25
Consumption of stores and spare parts	10.07	4.94
Power & Fuel	3.98	0.10
Rent	84.29	37.06
Repairs to machinery	0.88	0.49
Repairs to Building	14.23	2.08
Insurance	1.64	0.37
Miscellaneous expenses		
- Professional Fees	32.07	4.24
- Travelling & Conveyance Exp	311.85	182.84
- Commission Exp	80.09	14.26
- ROC & Compliance Exp	0.08	0.06
- Sales and Promotion Expenses	9.98	-
- Legal Expenses	2.94	-
- Other Mic Exp	20.41	3.59
Total	572.93	250.29

BOARD REPORT TO THE MEMBERS

To the Share Holders for the year ended 31st March, 2023

To,
The Share Holders,

Your Directors present the company's 6th Annual Report on the business and operations of the Company along with the Audited Balance Sheet and Profit & loss Account for the year ended 31st March 2023.

1. Financial summary and working results: -

(In Thousand)

	For the year 2022-23	For the year 2021-22
Gross Income	5907.69	4446.79
(Loss)/Profit before Tax	63.92	4.14
Tax Expense	(16.58)	(1.44)
(Loss)/Profit After Tax	47.34	2.70
Balance b/f from previous year	467.02	22.62
Less: Appropriation	0	0
Balance c/f to Balance Sheet	514.36	467.02

2. Reserves & Surplus

Out of the total profit of Rs. **514.36** for the Financial Year, entire amount is proposed to be transferred to the General Reserve.

3. Dividend

No dividend was declared for the year 2022-2023.

4. Brief description of the company's working during the year/state of company's affair

Company is dealing in trading of pharmaceuticals items. Company is dedicated to provide genuine medicines to society at reasonable rate.

Events subsequent to the date of Financial Statements

There is n material changes and commitments affecting the financial position of the company occurred between the end of the financial year of the company to which the financial statements relate and the date of the report.

6. Significant & Material orders passed by the regulators

During the year no significant and material orders passed by the regulators or courts or tribunals impacting the going concern status and company's operations in future.

7. Details of Subsidiaries and Associates

Details of the Companies which have become / ceased to be its Subsidiary/ JV/ Associate Company

S.No	Name	Status Subsidiary z/JV/ Associate company	Date of becoming Subsidiary/ JV/ Associate Company	Date of ceasing as Subsidiary/ JV/ Associate Company
1	Chandan Healthcare Limited	Holding Company	26/02/2022	--

8. Deposits

There are no Deposits accepted during the year and no balance outstanding at the year end.

9. Changes in share capital

There are no changes in share capital of the company.

10. Statutory Auditors

Pursuant to provisions of Section 139 and other applicable provisions and relevant rules of the Companies Act, 2013, M/s Gagan Jain & Associates, were appointed as the auditors of the Company for a term of five consecutive years till the year 2027.

However, M/s Gagan Jain & Associates vide its letter dated 10th June, 2023 resigned as the Statutory Auditors of the Company. The Board of Directors, noted and accepted the resignation of M/s Gagan Jain & Associates.

Further, Board approved the appointment of M/s MSNT & Associates LLP, Chartered Accountants (Firm Registration No. 018542C) to fill the casual vacancy subject to the approval of shareholders in the extra-ordinary general meeting which was held on 7th July, 2023. The Shareholders approved appointment of new auditors to hold office till the ensuing Annual General Meeting of the Company.

Accordingly, their tenure comes to end at this Annual General Meeting. The Board of Directors of the Company has recommended the re-appointment of M/s MSNT & Associates LLP, Chartered Accountants as the Statutory Auditors of the Company, subject to shareholder's approval, to hold office for a term of 5 consecutive years from the 20th Annual General Meeting till the conclusion of 25th Annual General to be held in the year 2028. The said matter shall be made part of the Notice convening the ensuing AGM. The Company has received from M/s M/s MSNT & Associates LLP, Chartered Accountants, the consent confirming the willingness and eligibility to be appointed as the Auditors of the Company as per the provisions of Section 141 of the Companies Act, 2013.

12. Environment, safety and energy conservation

The relevant data pertaining to conservation of energy, technology absorption and other details are mentioned below:

Conservation of Energy:

The contribution by the company towards conservation of energy is limited to in house, office administration and operational process. Company has taken precautions and has made all efforts for conservation of energy. Company's operation does not consume significant amount of energy.

Technology Absorption: - Company constantly makes efforts to use latest Technologies.

Research and Development: - NA

Benefits derived as a result of the above R&D efforts :- NA

13. Foreign exchange earnings and outgo

During the year the total foreign exchange earned was NIL and utilized also was NIL.

14. Disclosure under the sexual harassment of women at workplace(Prevention, Prohibition and Redressal) Act, 2013

The company has in place a policy for prevention of sexual harassment in accordance with the requirements of the Sexual Harassment of women at workplace (Prevention, Prohibition & Redressal) Act, 2013. Internal Complaints Committee has been set up to redress complaints received regarding sexual harassment. All employees (permanent, contractual, temporary, trainees) are covered under this policy. The Company did not receive any complain during the year 2022-23.

15. Number and Date of meetings of the Board of Directors

Ten Board meeting were held during the year, details of which are as follows:-

S.No.	Date of Meeting
1	15/04/2022
2	22/06/2022
3	23/08/2022
4	01/09/2022
5	02/09/2022
6	25/12/2022
7	04/02/2023
8	23/02/2023
9	03/03/2023
10	15/03/2023

16. The following table gives the attendance record of the directors at the above said Board Meetings and at the last Annual General Meeting

Director	No. of Board Meetings Held	No. of Board Meetings Attended	Last AGM Attended
Dr.Amar Singh	10	10	Yes
Asmita Singh	10	10	Yes
Anant Singh	10	10	Yes
Rajeev Nain	10	10	Yes
Vinay Lamba	10	10	Yes
Aasti Singh	10	10	Yes

17. Particulars of loans, guarantees or investments under section 186

S.N.	Particulars of Loans, Guarantee & Investments	Nature	Amount
1.	Shares in Chandan Institute Of Medical Sciences Limited	Investment	42,50,000

18. Particulars of contracts or arrangements with related parties

NIL

19. Corporate Governance

All the directors do not receive any benefit from the company except salary as follows:-

S.No.	NAME OF THE DIRECTOR	TOTAL SALARY
1	Dr.Amar Singh	NIL
2	Asmita Singh	NIL
3	Anant Singh	60,00,000
4	Rajeev Nain	NIL
5	Vinay Lamba	NIL
6	Aasti Singh	NIL

As the liability for Gratuity is provided on an actuarial basis for the Company as a whole, the amount pertaining to Directors is not ascertainable and, therefore, not included in the above.

20. Risk Management Policy

Risk Management Policy at Chandan Pharmacy Limited seeks to identify the following risks

- Corporate Strategy Risk
- Management Risk
- Operational Risks

and provides guidelines to define, measure, report, control and mitigate the identified risks.

The objective of Risk Management at Chandan Pharmacy Limited is to create and protect shareholder value by minimizing threats or losses, and identifying and maximizing opportunities and includes:-

1. Providing a framework that enables future activities to take place in a consistent and controlled manner
2. Improving decision making, planning and prioritization by comprehensive and structured understanding of business activities, volatility and opportunities/ threats
3. Contributing towards more efficient use/ allocation of the resources within the organization
4. Protecting and enhancing assets and company image
5. Developing and supporting people and knowledge base of the organization.
6. Optimizing operational efficiency

Every employee who identifies any potential risk shall report to his senior or departmental head further Risk Identification is obligatory on all functional directors and departmental heads who with the inputs from their team members are required to report the material risks to the Chairman and Managing Director along with their views and recommendations for risk minimization.

The Board shall authorize a executive team to implement the approved strategy and team shall submit its report on timely basis to ascertain the risk minimization or elimination.

21. Transfer of amounts to investor education and protection Fund

Company did not have any funds lying unpaid or unclaimed for a period of seven years. Therefore there were no funds which were required to be transferred to Investor Education and Protection Fund (IEPF).

22. Directors' Responsibility Statement

The Directors' Responsibility Statement referred to in clause (c) of sub-section (3) of Section 134 of the Companies Act, 2013, shall state that—

- in the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;
- the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- the directors had prepared the annual accounts on a going concern basis; and
- the directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

23. Acknowledgement

The Directors commend the continuing commitment and dedication of employees at all levels. The Directors would also like to thank all other stakeholders, Bankers & other business associates, who have provided sustained support and encouragement. The Directors look forward to their continued support in the years to come.

For & On Behalf of Board of Directors
Chandan Pharmacy Limited



(Dr. Amar Singh)
Director
DIN:01096328

Date: - 02/09/2023
Place: - Lucknow



(Mrs. Asmita Singh)
Director
DIN:01098055

R/O: 40, Chandan Vihar, Faridinagar,
Lucknow-226015

R/O: 40, Chandan Vihar, Faridinagar,
Lucknow-226015



CHANDAN PHARMACY LIMITED

Reg Off. Add.: A-15, VIVEK VIHAR, PHASE-1, DELHI-110095

CIN: U52601DL2017PLC322118

www.chandan.co.in



NOTICE TO MEMBERS

Notice is hereby given that the 6th Annual General Meeting of the Share Holders of the company will be held at corporate office of the company at Biotech Park, Sector-G, Jankipuram, Lucknow on 30/09/2023 at 12:00 to transact the following businesses:

ORDINARY BUSINESS BY ORDINARY RESOLUTION

1. To Approve and adopt the audited Balance Sheet as at 31st March 2023 and the Statement of Profit & Loss Account for the Year ended on that date along with Auditors Report and Directors Report thereon. To consider and if thought fit to pass with or without modification(s) the following resolution as an Ordinary Resolution :

"RESOLVED THAT the Audited Balance Sheet and the Statement of Profit & Loss Account, Directors' Report and Auditors' Report for the year ended on 31st March, 2023 together with the schedules mentioned therein be and are hereby approved and adopted "

2. To appoint a director in place of Mr. Anant Singh, who retires by rotation and being eligible offers himself for re-appointment.

3. Appointment of statutory auditors

Pursuant to provisions of Section 139 and other applicable provisions and relevant rules of the Companies Act, 2013, M/s Ashish Mishra & Associates , were appointed as the auditors of the Company for a term of five consecutive years i.e. from the year 2020 to the year 2025.

However, Ashish Mishra & Associates vide its letter dated 10th June, 2023 resigned as the Statutory Auditors of the Company. The Board of Directors, noted and accepted the resignation of M/s Ashish Mishra & Associates.

Further, Board approved the appointment of M/s MSNT & Associates LLP, Chartered Accountants (Firm Registration No. 018542C) to fill the casual vacancy subject to the approval of shareholders in the extra-ordinary general meeting which was held on 7th July, 2023. The Shareholders approved appointment of new auditors to hold office till the ensuing Annual General Meeting of the Company.

To consider and if thought fit to pass with or without modification(s) the following resolution as an Ordinary Resolution :





Since 1997



Resolved that pursuant to the provisions of Section 139(8) and other applicable provisions if any, of the Companies Act, 2013 as amended from time to time or any other law for the time being in force (including any statutory modification or amendment thereto or re-enactment thereof for the time being in force), M/s. MSNT & Associates LLP , Chartered Accountants, Noida be and are hereby appointed as Statutory Auditors of the Company to fill the casual vacancy caused by the resignation of M/S Ashish Mishra & Associates Chartered Accountants on such remuneration as may be fixed by the Board of Directors in consultation with them."

SPECIAL BUSINESS BY ORDINARY RESOLUTION

ITEM#4. APPOINTMENT OF AN EXECUTIVE DIRECTOR

RESOLVED THAT pursuant to the provisions of Sections 149, 152 and other applicable provisions if any, of the Companies Act, 2013, and the Articles of Association of the Company, Mr. Vikas Lamba (DIN: 00925007), in respect of whom the Company has received notice signifying his candidature as director, be and is hereby appointed as an Executive Director of the Company with effect from 30th September, 2023(subject to approval of shareholders in Annual General Meeting) who shall be liable to retire by rotation."

RESOLVED FURTHER THAT the Board be and is hereby authorized to take such steps as may be necessary for obtaining necessary approvals - statutory, contractual or otherwise, in relation to the above and to settle all matters arising out of and incidental thereto and to sign and execute deeds, applications, documents and writings that may be required, on behalf of the Company and generally to do all such other acts, deeds, matters and things as may be necessary, proper, expedient or incidental for giving effect to this Resolution."

For & On Behalf of Board of Directors
Chandan Pharmacy Limited

Date: - 02/09/2023
Place: -Lucknow




(Dr. Amar Singh)
Director
DIN:01096328




(Mrs. Asmita Singh)
Director
DIN:01098055

R/O: 40, Chandan Vihar, Faridinagar,
Lucknow-226015

R/O: 40, Chandan Vihar, Faridinagar,
Lucknow-226015



NOTES:

1. A member entitled to attend and vote at the meeting is entitled to appoint a proxy to attend and vote, instead of himself/herself, and such proxy need not be a member of the company. proxy in order to be effective must be filed with the company at its registered office not later than forty eight hours before the meeting.
2. Corporate members intending to send their authorised representatives to attend the Meeting, are requested to send a certified copy of the Board Resolution authorising their representative to attend and vote on their behalf, at the Meeting.
3. The members are requested to intimate the change of address immediately to the company.
4. All documents referred to in accompanying Notice shall be open for inspection at the Registered Office of the Company during the office hours on all working days between 10 am to 6 pm up to the date of conclusion of AGM.
5. Explanatory Statement as required under Section 102(1) of the Companies Act, 2013, relating to the Special Business to be transacted at the Meeting is annexed hereto.